カニクイザルのブレオマイシン肺線維症モデル

【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of pulmonary function. Although many bleomycin-induced pulmonary fibrosis has been studied as IPF model in rodent, IPF model in nonhuman primates has...

Full description

Saved in:
Bibliographic Details
Published in日本薬理学会年会要旨集 p. 1-P-123
Main Authors 岡林, 佐知, 櫻庭, 峻, 安田, 仁, 山之内, 智彦, 佐々木, 麻衣, 光岡, ちほみ, 山崎, 則之, 館田, 智昭, 北島, 俊一
Format Journal Article
LanguageJapanese
Published 公益社団法人 日本薬理学会 2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract 【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of pulmonary function. Although many bleomycin-induced pulmonary fibrosis has been studied as IPF model in rodent, IPF model in nonhuman primates has not been reported. In this study, we investigate a cynomolgus monkey model of bleomycin-induced pulmonary fibrosis by IPF related biomarker and pathology. 【Methods】Two cynomolgus monkeys were injected transtrachealy with bleomycin (2mg/kg) once a week for the first 2 weeks. The blood and bronchoalveolar lavage fluid (BALF) were collected at 0, 1, 4, 7, 9, 14, 21, 28 days after the first bleomycin injection, and cytokine levels were measured. On day 29, lung hydroxyproline content was measured. The formalin fixed lungs were stained with HE or Masson's trichrome for microscopic observation. 【Result and Discussion】 After bleomycin injection, BALF IL-1β levels were significantly increased on day 1 and returned almost normal level on day 4. The BALF MCP-1 levels were gradually increased and reached peak from day 4 to day 9. The BALF TGF-beta1 levels reached the maximum on days 7 or 9. The serum TGF-beta1 levels showed almost the same tendency as the BALF levels. The lung hydroxyproline contents of bleomycin injected monkeys were increased about 1.4 times more than normal. Histological examination showed a significant interstitial fibrosis with destruction of the alveolar architecture and was similar to IPF of human. This study provided new model using nonhuman primate for drug development in IPF.
AbstractList 【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of pulmonary function. Although many bleomycin-induced pulmonary fibrosis has been studied as IPF model in rodent, IPF model in nonhuman primates has not been reported. In this study, we investigate a cynomolgus monkey model of bleomycin-induced pulmonary fibrosis by IPF related biomarker and pathology. 【Methods】Two cynomolgus monkeys were injected transtrachealy with bleomycin (2mg/kg) once a week for the first 2 weeks. The blood and bronchoalveolar lavage fluid (BALF) were collected at 0, 1, 4, 7, 9, 14, 21, 28 days after the first bleomycin injection, and cytokine levels were measured. On day 29, lung hydroxyproline content was measured. The formalin fixed lungs were stained with HE or Masson's trichrome for microscopic observation. 【Result and Discussion】 After bleomycin injection, BALF IL-1β levels were significantly increased on day 1 and returned almost normal level on day 4. The BALF MCP-1 levels were gradually increased and reached peak from day 4 to day 9. The BALF TGF-beta1 levels reached the maximum on days 7 or 9. The serum TGF-beta1 levels showed almost the same tendency as the BALF levels. The lung hydroxyproline contents of bleomycin injected monkeys were increased about 1.4 times more than normal. Histological examination showed a significant interstitial fibrosis with destruction of the alveolar architecture and was similar to IPF of human. This study provided new model using nonhuman primate for drug development in IPF.
Author 山之内, 智彦
櫻庭, 峻
館田, 智昭
岡林, 佐知
光岡, ちほみ
安田, 仁
佐々木, 麻衣
山崎, 則之
北島, 俊一
Author_xml – sequence: 1
  fullname: 岡林, 佐知
  organization: (株)新薬リサーチセンター
– sequence: 2
  fullname: 櫻庭, 峻
  organization: (株)新薬リサーチセンター
– sequence: 3
  fullname: 安田, 仁
  organization: (株)新薬リサーチセンター
– sequence: 4
  fullname: 山之内, 智彦
  organization: (株)新薬リサーチセンター
– sequence: 5
  fullname: 佐々木, 麻衣
  organization: (株)新薬リサーチセンター
– sequence: 6
  fullname: 光岡, ちほみ
  organization: (株)新薬リサーチセンター
– sequence: 7
  fullname: 山崎, 則之
  organization: (株)新薬リサーチセンター
– sequence: 8
  fullname: 館田, 智昭
  organization: (株)新薬リサーチセンター
– sequence: 9
  fullname: 北島, 俊一
  organization: (株)新薬リサーチセンター
BookMark eNo9j7tKA0EYhQdRMMY8go-wcS47mZlKJBgVAqbQevj3pruscdmNhaU7hYV9BAsLsTJeCiEBX-cv4mMYr8134HA48K2R5eHZMCZkg9E249LfzIqqOi-KvG1Em1rmDTzGxRJpcF9IzzdSrJJWVaUB9VlHdqTUDbKF9QTdNdavWD9gPUU3wcsXdGN0T1g_orv77mfo3j7q9_nsdj59nt9cobtHt-BknawkkFdx6zeb5Ki3c9jd8_oHu_vd7b6XcUGpBxL82AgRRDqgTFPFFWUyApBS8Y4yKgm5NkoHcWKCiIYqCXygEQUNkRYqEk3S-_nNqhEcx7Yo01MoLyyUozTMY_unbo2w9AvMDuzC_n8QnkBpMxCfLiBwXw
ContentType Journal Article
Copyright 2020 本論文著者
Copyright_xml – notice: 2020 本論文著者
DOI 10.1254/jpssuppl.93.0_1-P-123
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 2435-4953
ExternalDocumentID article_jpssuppl_93_0_93_1_P_123_article_char_ja
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
M~E
ID FETCH-LOGICAL-j2300-a5a4e933bd8b0180727015daa55726797fc28978bef9bd0c7fb4a0d0a8ad837d3
IngestDate Wed Apr 05 02:30:27 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Japanese
LinkModel OpenURL
MeetingName 日本薬理学会年会要旨集 第93回日本薬理学会年会
MergedId FETCHMERGED-LOGICAL-j2300-a5a4e933bd8b0180727015daa55726797fc28978bef9bd0c7fb4a0d0a8ad837d3
Notes 93_1-P-123
OpenAccessLink https://www.jstage.jst.go.jp/article/jpssuppl/93/0/93_1-P-123/_article/-char/ja
ParticipantIDs jstage_primary_article_jpssuppl_93_0_93_1_P_123_article_char_ja
PublicationCentury 2000
PublicationDate 2020
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – year: 2020
  text: 2020
PublicationDecade 2020
PublicationTitle 日本薬理学会年会要旨集
PublicationYear 2020
Publisher 公益社団法人 日本薬理学会
Publisher_xml – name: 公益社団法人 日本薬理学会
SSID ssib041656558
ssib044754519
ssib041654217
Score 1.824586
Snippet 【Purpose】Idiopathic pulmonary fibrosis (IPF) is a progressive and intractable lung disease characterized by the proliferation of fibroblasts and loss of...
SourceID jstage
SourceType Publisher
StartPage 1-P-123
SubjectTerms lung
Title カニクイザルのブレオマイシン肺線維症モデル
URI https://www.jstage.jst.go.jp/article/jpssuppl/93/0/93_1-P-123/_article/-char/ja
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 日本薬理学会年会要旨集, 2020, pp.1-P-123
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR09b9UwMCplYUEgQHyrA55QHnESx_ZUxa95qhhQh1bqFsUvyfCGUqF2YUAiGRjYQWJgQEw8PgakVuJP8CM8PH4Gd87HC7QDLVJkXc7nu_OdE99FtuM4D7IioEE5LdxQl6ELb0nmSggb3Cxkmkea-rS0C2SfRJs74eNdtrty4edg1dLhgR5Nn5-6r-Q8XgUc-BV3yZ7Bsz1TQAAM_oUSPAzlP_mYJAERPomVBeBSHWbSAWELqKilaYkpiZMWI_uqcdcq7qqSE3x4W6UCkgiLAWKOeNkAEYk3EJCciI449jsNe4wahsUkiZA-ZhYYW00EKoYAsPKIACUZco4BCIkaW3GMKElUOMAIJIDetQwFSSSRioj-A6RtBB1qSBKkglFmOWygIBQ3AU2W9BHaTCnbMEYVLD1DCyg1ZAsWFdIyAGZezxak0z-kU7ywRlqPMeycYA096CStSRnqE0fDrzK-1z9BthXrzAMSrO3BSyrBKsDEATIDHSWzsmK4Hp7Pzs0kbmcLH-JeFxcLD2Yj6m65tNnOfWKm9FmIM-U-PN2Q7oxkMIJscEn_1yHk7RBPO_pUBqmHBU23UmiSdgS4VzCdQcJy0eeQeuNa2hdJ94IPceucv8yn8T4anDeHh0_icUftTjtQ8dGpCkK0OIPcqVt3aUPB7SvO5TaHW4sbZa46K7PsmrNuqrmpX5vqm6k-murI1HPz8qup35j6s6k-mfq9xR-b-vuv6sfi-N3i6Mvi7StTfzA1lPPrzs4k2R5vuu3fSdwZpO2em7EsLGQQ6FxoPAUPEgEIrfMsY4z7EZe8nPpCcqGLUurcm_JSh5mXe5nIchHwPLjhrO493StuOmu8lGGkJdUSZkeGP3gofa2nGdUwtCjlt5z1pr_pfnMETXpWf9z-bw53nEs4zpuvj3ed1YNnh8U9iMcP9H3r499kP7Fa
link.rule.ids 315,786,790,4043,27956,27957,27958
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%82%AB%E3%83%8B%E3%82%AF%E3%82%A4%E3%82%B6%E3%83%AB%E3%81%AE%E3%83%96%E3%83%AC%E3%82%AA%E3%83%9E%E3%82%A4%E3%82%B7%E3%83%B3%E8%82%BA%E7%B7%9A%E7%B6%AD%E7%97%87%E3%83%A2%E3%83%87%E3%83%AB&rft.jtitle=%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A%E5%B9%B4%E4%BC%9A%E8%A6%81%E6%97%A8%E9%9B%86&rft.au=%E5%B2%A1%E6%9E%97%2C+%E4%BD%90%E7%9F%A5&rft.au=%E6%AB%BB%E5%BA%AD%2C+%E5%B3%BB&rft.au=%E5%AE%89%E7%94%B0%2C+%E4%BB%81&rft.au=%E5%B1%B1%E4%B9%8B%E5%86%85%2C+%E6%99%BA%E5%BD%A6&rft.date=2020&rft.pub=%E5%85%AC%E7%9B%8A%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A&rft.eissn=2435-4953&rft.spage=1-P-123&rft_id=info:doi/10.1254%2Fjpssuppl.93.0_1-P-123&rft.externalDocID=article_jpssuppl_93_0_93_1_P_123_article_char_ja